FibroBiologics (NASDAQ:FBLG) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of FibroBiologics (NASDAQ:FBLG) in a report released on Thursday morning,Benzinga reports. The brokerage currently has a $12.00 price objective on the stock.

Other research analysts have also issued research reports about the stock. Rodman & Renshaw initiated coverage on shares of FibroBiologics in a research note on Thursday, December 12th. They set a “buy” rating and a $12.00 price objective on the stock. D. Boral Capital reiterated a “buy” rating and set a $16.00 price target on shares of FibroBiologics in a research report on Friday, December 27th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, FibroBiologics has a consensus rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Price Performance

FibroBiologics stock opened at $1.29 on Thursday. FibroBiologics has a 52 week low of $1.08 and a 52 week high of $17.75. The company’s 50-day moving average price is $1.98 and its two-hundred day moving average price is $2.49.

Institutional Trading of FibroBiologics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company acquired a new position in FibroBiologics in the third quarter worth approximately $32,000. Jane Street Group LLC bought a new stake in shares of FibroBiologics during the 3rd quarter worth $37,000. Intech Investment Management LLC acquired a new position in shares of FibroBiologics in the 4th quarter worth $25,000. Virtu Financial LLC acquired a new stake in shares of FibroBiologics during the fourth quarter worth $30,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of FibroBiologics during the fourth quarter worth $37,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.